Literature DB >> 18086002

Endothelial nitric oxide synthase gene: prospects for treatment of heart disease.

Glen E Cooke1, Amit Doshi, Philip F Binkley.   

Abstract

Nitric oxide functions as a signaling molecule with a well-established role in vascular homeostasis. It is synthesized from the oxidation of L-arginine by the enzyme, endothelial nitric oxide synthase (eNOS). The eNOS gene has a number of polymorphic sites, including SNPs, dinucleotide repeats and variable number tandem repeat sequences, and the opportunity exists to investigate polymorphic functional correlates as well as disease-specific associations, especially in cardiovascular disease, including coronary artery disease, and its most severe consequence, myocardial infarction. A number of clinical and functional correlative studies involving eNOS polymorphisms have been reported and are presented. The promise and complexity of pharmacogenetics is illustrated using eNOS as an example because of its relationship with cardiovascular biology and pathology. In this review, we will discuss the impact of nitric oxide, eNOS, genetic regulation, clinical investigation and, ultimately, prospects for treatment of heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086002     DOI: 10.2217/14622416.8.12.1723

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  15 in total

1.  Endothelial nitric oxide synthase polymorphisms and haplotypes in genetic epidemiology and pharmacogenetics: remarks regarding a lack of association on the risk of myocardial infarction.

Authors:  Marcelo Rizzatti Luizon
Journal:  Mol Biol Rep       Date:  2014-01-07       Impact factor: 2.316

2.  A promoter polymorphism of the endothelial nitric oxide synthase gene is associated with reduced mRNA and protein expression in failing human myocardium.

Authors:  Amit A Doshi; Mark T Ziolo; Honglan Wang; Emily Burke; Amanda Lesinski; Philip Binkley
Journal:  J Card Fail       Date:  2010-02-07       Impact factor: 5.712

3.  Endothelial nitric oxide synthase inhibits the development of autoimmune-mediated vasculitis in mice.

Authors:  Trenton R Schoeb; Tambi Jarmi; M John Hicks; Scott Henke; Abolfazl Zarjou; Hitoshi Suzuki; Philip Kramer; Jan Novak; Anupam Agarwal; Daniel C Bullard
Journal:  Arthritis Rheum       Date:  2012-12

4.  An NOS3 Haplotype is Protective against Hypertension in a Caucasian Population.

Authors:  Georgios D Kitsios; Elias Zintzaras
Journal:  Int J Hypertens       Date:  2010-03-25       Impact factor: 2.420

5.  Endothelial nitric oxide synthase gene polymorphisms and the risk of acute myocardial infarction in a South Indian population.

Authors:  Annan Sudarsan Arun Kumar; Gurusamy Umamaheswaran; Ramamoorthy Padmapriya; Jayaraman Balachandar; Chandrasekaran Adithan
Journal:  Mol Biol Rep       Date:  2012-10-29       Impact factor: 2.316

6.  Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.

Authors:  Xue Zhang; Amy I Lynch; Barry R Davis; Charles E Ford; Eric Boerwinkle; John H Eckfeldt; Catherine Leiendecker-Foster; Donna K Arnett
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

7.  Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: pharmacogenomic implications.

Authors:  Manjula Bhanoori
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

8.  The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.

Authors:  Paula Juliet Williams; Linda Morgan
Journal:  Pharmgenomics Pers Med       Date:  2012-01-20

9.  Is there a relationship between endothelial nitric oxide synthase gene polymorphisms and ankylosing spondylitis?

Authors:  Ismail Sari; Yusuf Ziya Igci; Gercek Can; Ali Taylan; Dilek Solmaz; Bulent Gogebakan; Servet Akar; Zeynep Eslik; Giray Bozkaya; Nurullah Akkoc
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

10.  The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus.

Authors:  Jacob Odeberg; Charlotte A Larsson; Lennart Råstam; Ulf Lindblad
Journal:  BMC Cardiovasc Disord       Date:  2008-12-10       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.